Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
Diabetes Care · 01.05.2023 · 46 (5) · 1060-1067
DOI: 10.2337/dc22-2396 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 21.03.2023. Verfasst von Juliana M Bue-Valleskey und 8 weiteren Autor:innen. Beteiligte Einrichtung: 1Eli Lilly and Company, Indianapolis, IN. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed the safety and efficacy of BIF versus degludec in insulin-naive patients with type 2 diabetes (T2D) previously treated with oral antihyperglycemic medications. RESEARCH DESIGN AND METHODS During this randomized, parallel, open-label study, 278 insulin-naive patients with T2D were randomly assigned (1:1) to receive BIF once weekly or degludec once daily over the 26-week treatment period. Both groups were titrated to fasting glucose of 80–100 mg/dL (4.4 to <5.6 mmol/L). The primary end point was HbA1c change from baseline to week 26 (noninferiority margin 0.4%). Secondary end points included fasting blood glucose (FBG), six-point glucose profiles, and rate of hypoglycemia. RESULTS After 26 weeks of treatment, BIF demonstrated a noninferior HbA1c change from baseline versus degludec, with a treatment difference of 0.06% (90% CI −0.11, 0.24; P = 0.56). Both BIF and degludec treatment led to significant reductions in FBG from baseline. At week 26, the between-treatment difference for BIF versus degludec was 4.7 mg/dL (90% CI 0.1, 9.3; P = 0.09). The rate of level 2 hypoglycemia was low and not significantly different between treatment groups (BIF 0.22 events/patient/year, degludec 0.15 events/patient/year; P = 0.64); there was no severe hypoglycemia. The occurrence of treatment-emergent adverse events was also similar between BIF and degludec. CONCLUSIONS Once-weekly BIF achieved excellent glycemic control similar to degludec, with no concerning hypoglycemia or other safety findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Eli Lilly and Company, Indianapolis, IN.
- 2Lilly France, Neuilly sur Seine, France.
- 3Velocity Clinical Research, Los Angeles, CA.
ORCID-Profile: Juliana M Bue-Valleskey
Förderung
- Eli Lilly and Company
Zitieren
APA
Bue-Valleskey, J. M., Kazda, C. M., Ma, C., Chien, J., Zhang, Q., Chigutsa, E., Landschulz, W., Haupt, A., & Frias, J. P. (2023). Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care, 46(5), 1060-1067. https://doi.org/10.2337/dc22-2396
Vancouver
Bue-Valleskey JM, Kazda CM, Ma C, Chien J, Zhang Q, Chigutsa E, et al. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care. 2023;46(5):1060-1067. doi:10.2337/dc22-2396
BibTeX
@article{BueValleskey2023,
author = {Bue-Valleskey, Juliana M and Kazda, Christof M and Ma, Chenchen and Chien, Jenny and Zhang, Qianyi and Chigutsa, Emmanuel and Landschulz, William and Haupt, Axel and Frias, Juan P},
title = {Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial},
journal = {Diabetes Care},
year = {2023},
volume = {46},
number = {5},
pages = {1060--1067},
doi = {10.2337/dc22-2396}
}
EUVIMED